#1 Clinical Trials Search in Europe

Ezabenlimab

Ezabenlimab is an innovative immunotherapy drug currently being studied in various clinical trials for the treatment of advanced cancers. This article provides an overview of ongoing research investigating Ezabenlimab alone and in combination with other therapies for solid tumors and other malignancies. We’ll explore the potential benefits, study designs, and key findings from these cutting-edge clinical trials.

Table of Contents

What is Ezabenlimab?

Ezabenlimab, also known as BI 754091, is a type of medicine called an immune checkpoint inhibitor. It belongs to a class of drugs that help the immune system fight cancer[1]. Ezabenlimab is currently being studied in various clinical trials to evaluate its effectiveness in treating different types of cancer.

How Does Ezabenlimab Work?

Ezabenlimab works by targeting a protein called PD-1 (Programmed Death-1) on immune cells. By blocking PD-1, ezabenlimab helps activate the body’s immune system to recognize and attack cancer cells more effectively[2]. This mechanism is similar to other well-known immunotherapy drugs like pembrolizumab.

Types of Cancer Treated with Ezabenlimab

Clinical trials are exploring the use of ezabenlimab in various types of cancer, including:

  • Non-small cell lung cancer (NSCLC): A common type of lung cancer[3]
  • Small cell lung cancer (SCLC): A less common, but aggressive form of lung cancer[1]
  • Colorectal cancer: Cancer of the large intestine or rectum[4]
  • Soft tissue sarcomas: Cancers that develop in soft tissues like muscles, fat, and blood vessels[5]
  • Neuroendocrine tumors: Cancers that arise from cells of the endocrine (hormone) and nervous systems[1]
  • Liver cancer (hepatocellular carcinoma)[3]
  • Pancreatic cancer[3]
  • Head and neck cancers[3]
  • Triple-negative breast cancer[6]
  • Biliary tract cancer: Cancer of the bile ducts[6]
  • Glioblastoma: An aggressive type of brain cancer[7]

Combination Therapies with Ezabenlimab

Many clinical trials are studying ezabenlimab in combination with other cancer treatments to potentially enhance its effectiveness. Some of these combinations include:

  • Ezabenlimab + Obrixtamig (BI 764532): For small cell lung cancer and neuroendocrine tumors[1]
  • Ezabenlimab + BI 765049: For various solid tumors[3]
  • Ezabenlimab + BI 907828 (Brigimadlin): For soft tissue sarcomas and other solid tumors[6]
  • Ezabenlimab + BI 836880: For non-small cell lung cancer and other solid tumors[8]
  • Ezabenlimab + BI 765063: For colorectal cancer[4]
  • Ezabenlimab + NK-92/5.28.z cells: For glioblastoma[7]

Clinical Trials Involving Ezabenlimab

Ezabenlimab is being studied in various phases of clinical trials, from early Phase I studies to more advanced Phase III trials. These studies aim to:

  • Determine the safe and effective dosage of ezabenlimab[1]
  • Evaluate how well patients tolerate the treatment[2]
  • Assess the effectiveness of ezabenlimab in shrinking tumors or slowing cancer growth[5]
  • Compare ezabenlimab to standard treatments or in combination with other therapies[5]
  • Study the effects of ezabenlimab on patients’ quality of life[5]

Potential Side Effects

As with any medication, ezabenlimab may cause side effects. Common side effects of immune checkpoint inhibitors like ezabenlimab can include:

  • Fatigue
  • Skin rashes
  • Diarrhea
  • Nausea
  • Fever

More serious side effects, though less common, may occur due to the immune system attacking healthy tissues. These can include inflammation in various organs. Doctors closely monitor patients for any adverse reactions during clinical trials[2].

Future Prospects

Ezabenlimab shows promise in the field of cancer immunotherapy. Ongoing clinical trials will help determine its effectiveness and safety profile. If successful, ezabenlimab could become an important treatment option for various types of cancer, either alone or in combination with other therapies[5].

As research continues, patients with cancer may have more treatment options in the future. It’s important for patients to discuss with their healthcare providers about the possibility of participating in clinical trials and whether ezabenlimab might be a suitable option for their specific condition.

Aspect Details
Drug Name Ezabenlimab (also known as BI 754091)
Drug Type Immune checkpoint inhibitor antibody
Administration Intravenous infusion, typically every 3 weeks
Cancer Types Studied Advanced solid tumors, including lung, colorectal, pancreatic, head and neck, and soft tissue sarcomas
Combination Therapies BI 765049, BI 836880, Brigimadlin, NK-92/5.28.z cells, and others
Primary Study Objectives Safety, tolerability, maximum tolerated dose, efficacy in tumor reduction, progression-free survival
Trial Phases Phase I, II, and III studies ongoing
Key Outcomes Measured Adverse events, objective response rate, duration of response, overall survival

FAQ

  • What is Ezabenlimab? Ezabenlimab is an antibody that may help the immune system fight cancer. It is classified as an immune checkpoint inhibitor, which works by enhancing the body's natural defenses against cancer cells.
  • What types of cancers are being studied with Ezabenlimab? Ezabenlimab is being investigated for various advanced solid tumors, including non-small cell lung cancer, colorectal cancer, pancreatic cancer, head and neck cancer, soft tissue sarcomas, and other neuroendocrine tumors.
  • How is Ezabenlimab administered in clinical trials? In most trials, Ezabenlimab is administered as an intravenous infusion, typically every 3 weeks. The exact dosing schedule may vary depending on the specific study design and combination therapies being tested.
  • What are some common combination therapies being tested with Ezabenlimab? Ezabenlimab is being studied in combination with various other drugs, including BI 765049, BI 836880, Brigimadlin, and NK-92/5.28.z cells. These combinations aim to enhance the anti-tumor effects and potentially improve outcomes for patients.
  • What are the main goals of the Ezabenlimab clinical trials? The primary objectives of these trials include assessing the safety and tolerability of Ezabenlimab, determining the maximum tolerated dose, evaluating its efficacy in shrinking tumors or slowing disease progression, and measuring overall survival rates in patients with advanced cancers.

Ongoing Clinical Trials on Ezabenlimab

  • Study of Ezabenlimab and Drug Combination for Stage III Anal Cancer Treatment

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study of ezabenlimab in patients with locally advanced head and neck cancer who have remaining signs of disease after chemoradiotherapy

    Not yet recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Belgium

  • Study on the Effects of Ezabenlimab and BI 907828 in Adult Patients with Advanced or Metastatic Solid Tumors

    Not recruiting

    1 1
    Investigated drugs:
    France

Glossary

  • Ezabenlimab: An antibody-based immunotherapy drug that may help the immune system fight cancer by acting as an immune checkpoint inhibitor.
  • Immune checkpoint inhibitor: A type of drug that blocks certain proteins made by immune system cells and some cancer cells, potentially allowing the immune system to attack cancer cells more effectively.
  • Solid tumors: Abnormal masses of tissue that usually do not contain cysts or liquid areas. Solid tumors may be benign or malignant.
  • Neuroendocrine tumors: Rare tumors that develop in cells of the neuroendocrine system, which is responsible for producing hormones and regulating various bodily functions.
  • Intravenous infusion: A method of delivering medications directly into the bloodstream through a vein using a needle or catheter.
  • Maximum tolerated dose (MTD): The highest dose of a drug or treatment that does not cause unacceptable side effects in patients.
  • Dose-limiting toxicity (DLT): Side effects that are severe enough to prevent an increase in the dose of a drug or treatment being tested in a clinical trial.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Objective response: A measurable reduction in tumor size or extent of cancer in response to treatment.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives with cancer without it worsening.

References

  1. https://clinicaltrials.gov/study/NCT05879978
  2. https://clinicaltrials.gov/study/NCT05471856
  3. https://clinicaltrials.gov/study/NCT06091930
  4. https://clinicaltrials.gov/study/NCT05446129
  5. https://clinicaltrials.gov/study/NCT06370871
  6. https://clinicaltrials.eu/trial/study-on-the-effects-of-ezabenlimab-and-bi-907828-in-adult-patients-with-advanced-or-metastatic-solid-tumors/
  7. https://clinicaltrials.gov/study/NCT03383978
  8. https://clinicaltrials.gov/study/NCT03468426